Single-use bioreactors offer significant advantages over conventional stainless steel bioreactors such as lower capital costs, ease of scalability, reduced validation requirements and improved process flexibility. Single-use bioreactors are particularly useful for R&D, pre-clinical and clinical manufacturing stages as they reduce the risks involved in developing new biologics. They enable smaller scaled production and allow for multiple parallel processes in a small footprint. Various tissue engineering and cell therapy manufacturing processes also rely heavily on single-use bioreactors.

The Global Single-Use Bioreactor Market is estimated to be valued at US$ 1541 Mn in 2024 and is expected to exhibit a CAGR of 17% over the forecast period 2024 To 2031.

Key Takeaways

Key players operating in the single-use bioreactor market are Thync Global Inc., Apple Inc., HVMN, Synbiota, MoodMetric, THE ODIN, and Fitbit, Inc. The increasing demand for disposable and flexible bioprocessing equipment from biopharmaceutical manufacturers is a major factor driving the growth of single-use bioreactors. With rise in adoption of single-use bioprocessing globally, several pharmaceutical companies are actively investing in enhancing their manufacturing capabilities using single-use technologies. Growing cell therapy and gene therapy sectors have fueled the demand for single-use bioreactors as they require robust bioreactor systems for efficient cell expansion and differentiation processes.

The global single-Use Bioreactor Market Size  is expected to expand significantly during the forecast period owing to growing demand for cost-effective and flexible biotherapeutic production along with rising preference for single-use technologies across major markets including North America, Europe and Asia Pacific regions. Several leading biopharmaceutical companies are establishing new single-use facility expansions worldwide to enhance their biomanufacturing capacity.

Market Key Trends

The single-use bioreactor market is witnessing growing integration of digitization and wireless sensing technologies. Modern single-use bioreactor systems are being integrated with Internet of Things (IoT) and wireless sensors to allow for real-time data collection and monitoring of various critical process parameters. This has enabled improved process analytical technology (PAT) integration and quality by design (QbD) based manufacturing. The application of predictive analytics on bioreactor data also helps in optimizing upstream and downstream processes. Integration of advanced sensing and digitization trends will continue to drive innovations in next-generation single-use bioreactor designs.

Porter’s Analysis
Threat of new entrants: Single-use bioreactors require high capital investments limiting entry of new players. Bargaining power of buyers: Large pharmaceutical companies have strong bargaining power to negotiate prices with single-use bioreactor suppliers. Bargaining power of suppliers: Dominance of few large players like Sartorius Stedim Biotech makes suppliers powerful in negotiating contracts. Threat of new substitutes: No major substitute technology exist for single-use bioreactors in biopharmaceutical manufacturing currently. Competitive rivalry: Intense competition exists among established players to continuously innovate and launch new single-use bioreactor systems.

The North American region accounts for the largest share in the global single-use bioreactor market in terms of value. This is majorly due to the presence of well-established biopharmaceutical industry and growing R&D investments by pharmaceutical companies and research institutes in the region. Rising demand for monoclonal antibodies and growth in demand for vaccines used for the treatment infectious diseases are also propelling market growth.

The Asia Pacific region is expected to witness the fastest growth over the forecast period in the single-use bioreactor market. This can be attributed to expansion of biopharmaceutical industry, rising patient pool, increasing healthcare expenditure, and growing investments by governments as well as private players to modernize healthcare infrastructure in emerging countries of the region. Additionally, tax incentives offered by various governments for setting up manufacturing facilities are also attracting biopharmaceutical players to invest in the Asia Pacific region.

*Note:
1.Source: Coherent Market Insights, Public sources, Desk research
2.We have leveraged AI tools to mine information and compile it

About Author - Ravina Pandya

Ravina Pandya,a content writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemicals and materials, etc. With an MBA in E-commerce, she has expertise in SEO-optimized content that resonates with industry professionals.  LinkedIn Profile